Latest News

WASHINGTON, DC — Vanda Pharmaceuticals Inc. (Nasdaq: VNDA) today announced that the U.S. Patent and Trademark Office has issued a notice of allowance for its PONVORY® (ponesimod) patent application, number 17/962,968, covering methods for reducing clinical management events before or during the treatment of multiple sclerosis and methods for reinitiating...
WASHINGTON, DC — Vanda Pharmaceuticals, Inc. today announced the publication of an article titled “The Efficacy of Tradipitant in Patients with Diabetic and Idiopathic Gastroparesis in Phase III Randomized Placebo-Controlled Clinical Trial” in the Clinical Gastroenterology and Hepatology Journal which follows a previously published study of tradipitant in the treatment...
WASHINGTON, DC — Vanda Pharmaceuticals, Inc. today announced the publication of an article titled “Efficacy and Safety of Iloperidone in Bipolar Mania: A Double-Blind, Placebo-Controlled Study” in the Journal of Clinical Psychiatry. The findings of this pivotal study have been submitted to the U.S. Food and Drug Administration (FDA) as...
WASHINGTON, DC — Vanda Pharmaceuticals, Inc., today announced that the U.S. Food and Drug Administration (FDA) has approved the Investigational New Drug (IND) application to evaluate VCA-894A for the treatment of a patient with Charcot-Marie-Tooth disease, axonal, type 2S (CMT2S), caused by cryptic splice site variants within the IGHMBP2 gene. CMT2S...
Nashville, TN – By mapping the cellular and molecular geography of colorectal cancer, Vanderbilt University and Vanderbilt University Medical Center researchers collaboratively have discovered why most colorectal tumors escape detection and destruction by the body’s immune system. Their findings, reported in the journal Cell, could lead to new ways to...
A set of expert consensus-based, quality-of-care indicators identified considerable variability in the quality of pancreatic cancer care among hospitals and may be used to evaluate and identify areas for improvement, according to a new study in the June 9 online issue of the Journal of the National Cancer Institute. Factors...
PARIS – Variant, a company dedicated to developing innovative treatments for inherited eye orphan diseases, announces the decision of the European Commission to grant Orphan Drug Designation (ODD) for VAR002 for the treatment of Leber congenital amaurosis (LCA) and Cone-rod dystrophy (CORD). The decision is based on a positive opinion...
Combination therapies including venetoclax and another therapy have displayed promising results against subtypes of acute myeloid leukemia (AML) that are particularly difficult to treat, including relapsed or refractory AML with a specific mutation, high-risk AML and treated secondary AML. Researchers from The University of Texas MD Anderson Cancer Center presented...